{"id":"controlled-withdrawal-of-beta-blockers","safety":{"commonSideEffects":[{"rate":null,"effect":"Rebound hypertension"},{"rate":null,"effect":"Rebound tachycardia"},{"rate":null,"effect":"Angina pectoris"},{"rate":null,"effect":"Myocardial infarction (in high-risk patients)"}]},"_chembl":{"chemblId":"CHEMBL605455","moleculeType":"Small molecule","molecularWeight":"915.97"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Beta-blockers work by blocking adrenergic receptors, reducing heart rate and blood pressure. Abrupt discontinuation can cause a sudden surge in sympathetic activity, leading to rebound hypertension, tachycardia, and angina. Controlled, gradual tapering allows the cardiovascular system to readjust to normal sympathetic tone without acute adverse events.","oneSentence":"Controlled withdrawal of beta-blockers is a clinical protocol that gradually reduces beta-blocker dosing to safely discontinue the medication and minimize rebound hypertension and tachycardia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:06.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Safe discontinuation of beta-blocker therapy in patients requiring medication cessation"},{"name":"Prevention of rebound hypertension and tachycardia upon beta-blocker withdrawal"}]},"trialDetails":[{"nctId":"NCT03671681","phase":"PHASE4","title":"Mindfulness Therapy for Chronic Migraine","status":"COMPLETED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2018-11-05","conditions":"Chronic Migraine, Medication Overuse Headache","enrollment":177},{"nctId":"NCT03549923","phase":"PHASE4","title":"Evaluation of Early CRRT InTerventions in Patients With ECMO(ELITE)","status":"COMPLETED","sponsor":"Beijing Anzhen Hospital","startDate":"2018-12-18","conditions":"Cardiogenic Shock","enrollment":131},{"nctId":"NCT04367051","phase":"NA","title":"Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2020-08-13","conditions":"Heart Failure","enrollment":62},{"nctId":"NCT03871803","phase":"PHASE4","title":"β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR)","status":"COMPLETED","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2018-10-01","conditions":"Heart Failure With Normal Ejection Fraction, Chronotropic Incompetence","enrollment":52},{"nctId":"NCT04621617","phase":"PHASE3","title":"Midodrine and Albumin in Patients With Refractory Ascites","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2020-11","conditions":"Refractory Ascites","enrollment":114},{"nctId":"NCT02770443","phase":"NA","title":"Withdrawal of Medication in Recovered DCM","status":"TERMINATED","sponsor":"McGill University","startDate":"2016-02-19","conditions":"Dilated Cardiomyopathy","enrollment":22},{"nctId":"NCT02200822","phase":"PHASE4","title":"Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients","status":"COMPLETED","sponsor":"Hasselt University","startDate":"2014-07","conditions":"Heart Failure (HF)","enrollment":80},{"nctId":"NCT02859311","phase":"PHASE4","title":"A Pilot Feasibility Study in Recovered Heart Failure","status":"UNKNOWN","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","startDate":"2016-04","conditions":"Heart Failure","enrollment":50},{"nctId":"NCT01850277","phase":"PHASE4","title":"Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2013-10","conditions":"Atrial Fibrillation, Heart Failure","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Controlled withdrawal of beta-blockers","genericName":"Controlled withdrawal of beta-blockers","companyName":"Fundación para la Investigación del Hospital Clínico de Valencia","companyId":"fundaci-n-para-la-investigaci-n-del-hospital-cl-nico-de-valencia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Controlled withdrawal of beta-blockers is a clinical protocol that gradually reduces beta-blocker dosing to safely discontinue the medication and minimize rebound hypertension and tachycardia. Used for Safe discontinuation of beta-blocker therapy in patients requiring medication cessation, Prevention of rebound hypertension and tachycardia upon beta-blocker withdrawal.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}